Search - tctmd.com

Displaying 101 - 120 of 1023

Sort: Relevancy | Date

Long-term Mortality After TAVI Lower With DOACs vs VKAs

News Conference News NY Valves 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

June 06, 2024

Temporary Pacemaker After TAVI May Preclude Long-term Pacing

News Conference News EuroPCR 2024

Temporary Pacemaker After TAVI May Preclude Long-term Pacing

May 24, 2024

POLMIDES: Hybrid Revascularization Bests CABG For 10-Year Survival

News Conference News EuroPCR 2024

POLMIDES: Hybrid Revascularization Bests CABG For 10-Year Survival

Yael L. Maxwell

May 22, 2024

Medicare Analysis Suggests Benefit of PFO Closure Beyond Age 60

News Conference News ESOC 2024

Medicare Analysis Suggests Benefit of PFO Closure Beyond Age 60

May 17, 2024

Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

News Conference News EuroPCR 2024

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

Michael O'Riordan

May 14, 2024

Women, Black Patients Less Likely to Get Advanced PE Therapy, Analysis Shows

News Conference News SCAI 2024

Women, Black Patients Less Likely to Get Advanced PE Therapy, Analysis Shows

May 06, 2024

Good Early Results for Conformable, ‘Single-Shot’ Pulsed-Field Ablation Catheter

News Conference News EHRA 2024

Good Early Results for Conformable, ‘Single-Shot’ Pulsed-Field Ablation Catheter

April 16, 2024

Pulmonary Embolism and Venous Disease: The Hottest Frontier of Endovascular Intervention

Presentation Fellows 2024

Pulmonary Embolism and Venous Disease: The Hottest Frontier of Endovascular Intervention

Presenter: Jay S. Giri

April 14, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

News Daily News

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

March 15, 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

Micra Leadless Pacemaker Performs Well Through 5 Years

News Daily News

Micra Leadless Pacemaker Performs Well Through 5 Years

March 06, 2024

Post PE Syndrome

Presentation THT 2024

Post PE Syndrome

Presenter: Paul Forfia

March 06, 2024

Contemporary Management of High-Risk PE: Focus on Temporary MCS Therapies and Surgical Thrombectomy

Presentation THT 2024

Contemporary Management of High-Risk PE: Focus on Temporary MCS Therapies and Surgical Thrombectomy

Presenter: Candice Lee

March 06, 2024

Case Resolution

Presentation THT 2024

Case Resolution

Presenter: Sareena George

March 06, 2024

Case Presentation

Presentation THT 2024

Case Presentation

Presenter: Sareena George

March 06, 2024

Risk Stratification and Treatment Goals of Acute PE

Presentation THT 2024

Risk Stratification and Treatment Goals of Acute PE

Presenter: Catalin Toma

March 06, 2024

Safety and Feasibility Assessment of the Doraya, a Renal Venous Afterload Modulator, for the Treatment of Volume Overload in Acute Heart Failure Patients with Insufficient Response to Diuretics

Presentation THT 2024

Safety and Feasibility Assessment of the Doraya, a Renal Venous Afterload Modulator, for the Treatment of Volume Overload in Acute Heart Failure Patients with Insufficient Response to Diuretics

Presenter: Lucas Zier

March 06, 2024

Debating the Role of T-TEER in the Sickest Patients

News Conference News THT 2024

Debating the Role of T-TEER in the Sickest Patients

Michael O'Riordan

March 05, 2024

CTO Diagnosed, Now What? European Experts Offer Advice on Revascularization

News Daily News

CTO Diagnosed, Now What? European Experts Offer Advice on Revascularization

February 09, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.